Skip to content

Galera Therapeutics, Inc.

Request correction

Corporate brand

Unclaimed

Galera Therapeutics, Inc. is a Malvern, United States-based company developing small molecules targeting cancer vulnerabilities, including SOD mimetics and NOS inhibitors.

Last updated September 16, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Galera Therapeutics, Inc. is a company in Malvern, United States. It develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. Its SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress; avasopasem is in trials for hormone-resistant advanced breast cancer. Its NOS inhibitor tilarginine (L-NMMA) inhibits NO production and is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer. The company states it is pioneering a new scientific approach with the goal of delivering new solutions for patients with breast cancer.

History

Galera Therapeutics, Inc. is a company in Malvern, United States. It develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. Its SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress; avasopasem is in trials for hormone-resistant advanced breast cancer. Its NOS inhibitor tilarginine (L-NMMA) inhibits NO production and is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer. The company states it is pioneering a new scientific approach with the goal of delivering new solutions for patients with breast cancer.

Products and positioning

Pioneering a new scientific approach with the goal of delivering new solutions for patients with breast cancer.

  • Avasopasem

    SOD mimetic in trials for hormone-resistant advanced breast cancer.

  • Rucosopasem

    SOD mimetic that mimics natural enzymes to convert superoxide into hydrogen peroxide.

  • Tilarginine (L-NMMA)

    NOS inhibitor undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer.

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/galera-therapeutics-inc-united-states · Editorial policy · How profiles are compiled